Ritlesitinib etkileşimleri

Additionally, concomitant use of ORENCIA with other biologic RA/PsA therapy or JAK inhibitors is not recommended. (Abatasept etiketi, Uyarılar ve önlemler)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (Ritlesitinib etiketi, Kutulu uyarı)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (Ritlesitinib etiketi, Kutulu uyarı)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (Ritlesitinib etiketi, Kutulu uyarı)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

Immunosuppressant/neoplastic: everolimus Co-administration of everolimus and PREZISTA/ritonavir is not recommended. irinotecan Discontinue PREZISTA/ritonavir at least 1 week prior to starting irinotecan therapy. (Darunavir etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (Ritlesitinib etiketi, Kutulu uyarı)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (Fludrokortizon etiketi, Uyarılar)

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. (Flunisolid etiketi, Önlemler)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (Ritlesitinib etiketi, Kutulu uyarı)

Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (İtrakonazol etiketi, İlaç etkileşimleri)

About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (Kaptopril etiketi, Uyarılar)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (Kladribin etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

…methylergonovine • HMG-CoA reductase inhibitors: lovastatin, simvastatin (these drugs can be temporarily discontinued to allow PAXLOVID use [see Table 2 , Drug Interactions (7.3) ] ) • Immunosuppressants: voclosporin • Microsomal triglyceride transfer protein inhibitor: lomitapide • Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists:… (Nirmatrelvir ve ritonavir etiketi, Kontrendikasyonlar)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (Ritlesitinib etiketi, Kutulu uyarı)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

In kidney, liver, and heart transplant patients Neoral may be administered with other immunosuppressive agents. (Siklosporin etiketi, Kutulu uyarı)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (Takrolimus etiketi, Kutulu uyarı)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (Ritlesitinib etiketi, Kutulu uyarı)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (Ritlesitinib etiketi, İlaç etkileşimleri)

• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (Ritlesitinib etiketi, Kutulu uyarı)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve olmesartan etiketi, İlaç etkileşimleri)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when coadministered. (Amlodipin ve valsartan etiketi, İlaç etkileşimleri)

Immunosuppressants: cyclosporine, sirolimus, tacrolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for these immunosuppressants when coadministered with REYATAZ. (Atazanavir etiketi, İlaç etkileşimleri)

Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

Therapeutic drug monitoring is recommended with concomitant use Immunosuppressant /neoplastic: everolimus ↑ immunosuppressants Co-administration of everolimus and PREZCOBIX or PREZCOBIX PED is not recommended. irinotecan Discontinue PREZCOBIX or PREZCOBIX PED at least 1 week prior to starting irinotecan therapy. (Darunavir ve kobisistat etiketi, İlaç etkileşimleri)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (Denosumab etiketi, Uyarılar ve önlemler)

Immuno-suppressants: e.g., cyclosporine (CsA) sirolimus tacrolimus ↑ immuno-suppressants ↑ elvitegravir (with CsA) ↑ cobicistat (with CsA) Therapeutic monitoring of the immunosuppressive agents is recommended upon coadministration with GENVOYA. (Elvitegravir, kobisistat, emtrisitabin ve tenofovir etiketi, İlaç etkileşimleri)

Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (Fenofibrat etiketi, İlaç etkileşimleri)

Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (Fenofibrik asit etiketi, İlaç etkileşimleri)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus ↑ Immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents. (Fosamprenavir etiketi, İlaç etkileşimleri)

Immunosuppressants everolimus, rapamycin (also known as sirolimus), temsirolimus budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, tacrolimus Rapamycin (sirolimus): Ketoconazole tablets 200 mg daily for 10 days increased the C max and AUC of a single 5 mg dose of sirolimus by 4.3 fold and 10.9 fold, respectively in 23 healthy… (Ketokonazol etiketi, İlaç etkileşimleri)

HBV reactivation has also been reported in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (Ledipasvir ve sofosbuvir etiketi, Uyarılar ve önlemler)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (Leflunomid etiketi, Uyarılar ve önlemler)

A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Merkaptopürin etiketi, Uyarılar ve önlemler)

Lymphoma and Other Malignancies Patients receiving immunosuppressants, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin [see Adverse Reactions ( 6.1 )]. (Mikofenolat etiketi, Uyarılar ve önlemler)

Immunosuppressive Agents There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. (Nefazodon etiketi, İlaç etkileşimleri)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Olmesartan, amlodipin ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (Penisilamin etiketi, Uyarılar)

HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (Sofosbuvir ve velpatasvir etiketi, Uyarılar ve önlemler)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Telmisartan ve amlodipin etiketi, İlaç etkileşimleri)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus etiketi, Uyarılar ve önlemler)

Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (Tinidazol etiketi, İlaç etkileşimleri)

In this study, current or past smokers had an additional increased risk of overall malignancies. (Ritlesitinib etiketi, Uyarılar ve önlemler)

Thirty-four patients were treated with corticosteroids and one patient was treated with a non-steroidal immunosuppressant. (Aksitinib etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persists despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Atorvastatin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (Ezetimib ve simvastatin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

IMNM is characterized by proximal muscle weakness and elevated serum CK, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive agents. (Fluvastatin etiketi, Uyarılar ve önlemler)

CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP1A2 inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP1A2 inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Lovastatin etiketi, Uyarılar)

CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP1A2 inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Metimazol etiketi, Uyarılar)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Immunosuppressive Drugs Tacrolimus: Tacrolimus has been shown to be metabolized via the CYP3A system. (Nifedipin etiketi, Önlemler)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Pitavastatin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Pravastatin etiketi, Uyarılar ve önlemler)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Propiltiourasil etiketi, Uyarılar)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Rosuvastatin etiketi, Uyarılar ve önlemler)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (Simvastatin etiketi, Uyarılar ve önlemler)

CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP1A2 inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP1A2 inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

Clinically Significant Interactions Affecting Other Drugs CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP3A inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)

CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP1A2 inhibitor. (Ritlesitinib etiketi, İlaç etkileşimleri)